Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Completed
Boehringer Ingelheim
Phase 4
2013-10-01
The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic
event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of
dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency
ablation, or cryoablation procedures.
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Completed
Vanderbilt University
Phase 4
2013-10-01
The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic
event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of
dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency
ablation, or cryoablation procedures.
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
Completed
Vanderbilt University Medical Center
Phase 4
2013-10-01
The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic
event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of
dabigatran use for peri-procedural anti-coagulation after left atrial catheter radiofrequency
ablation, or cryoablation procedures.
Drug Interaction Study Between Bosutinib And Dabigatran
Completed
Pfizer
Phase 1
2014-05-01
The study evaluates the effect of a single oral dose of bosutinib on the single dose
pharmacokinetics of dabigatran, a p-glycoprotein substrate, in healthy subjects.
A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants
Completed
Janssen Research & Development, LLC
Phase 1
2016-11-10
The purpose of this study is to evaluate the effect of steady-state concentrations of
odalasvir (ODV), as a single agent or in combination with simeprevir (SMV), on the
single-dose pharmacokinetics of dabigatran etexilate in healthy participants.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
